Ceapro Inc. Reports 2021 Third Quarter and Nine-Month Financial Results and Operational Highlights
– Increased R&D activities focused on the completion of a clinical trial for oat beta glucan as a potential cholesterol...
Year: 2021
Castellum, Inc. Announces Closing of Acquisition of Pax River Business
Castellum, Inc. Announces Closing of Acquisition of Pax River Business Castellum, Inc. (OTC: ONOV) announces closing the acquisition of certain...
VitalHub announced as a 2021 program winner on both the Deloitte Technology Fast 50™ and Fast 500™
TORONTO, Nov. 17, 2021 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSX: VHI) is pleased to announce the...
Sarepta Therapeutics Names Louise Rodino-Klapac, Ph.D., Head of Research and Development
Gilmore O’Neill, M.B., M.M.Sc., will depart the Company and serve in a consulting capacity through March 31, 2022CAMBRIDGE, Mass., Nov. 17,...
Longboard Pharmaceuticals Appoints Life Sciences Executive Dr. Jane Tiller to Board of Directors
SAN DIEGO, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing...
Sarepta Therapeutics Appoints Stephen L. Mayo, Ph.D., to its Board of Directors
A renowned expert in protein engineering, Dr. Mayo brings extensive scientific expertise and strong business acumen to the Company’s boardCAMBRIDGE,...
Denali Therapeutics Announces Strategic Partner Takeda Exercises Option to Co-Develop and Co-Commercialize DNL593 (PTV:PGRN)
— Companies to advance clinical development of DNL593 as a brain-penetrant progranulin replacement therapy for frontotemporal dementia-granulin (FTD-GRN) — SOUTH...
KLAS Research’s First Look Report Gives High Marks To Streamline Health’s eValuator™ Pre-Bill Coding Analysis Technology
Reviews how automated pre-bill coding analysis helps providers improve financial performance Atlanta, GA, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Streamline...
Agenus to Participate in 4th Annual Evercore ISI HealthCONx Conference
LEXINGTON, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of...
On the initiation of civil case
On the initiation of civil case The joint stock company “Olainfarm” hereinafter – the Company, informs that a civil case...
Spero Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying,...
Peer Reviewed Study Demonstrates MIMEDX Dehydrated Human Amnion Chorion Membrane (dHACM) Outperforms Standard of Care in Select Mohs Defect Reconstructions
MIMEDX PURION® Processed Placental Allografts Proved Safer Than Autologous Tissue, Reducing Infection, Scarring and Reoperation Rates MARIETTA, Ga., Nov. 17,...
MedArrive Announces $25 Million in Series A Funding to Bridge the Virtual Care Gap
Led by Section 32, new capital will accelerate platform buildout, network expansion to bring affordable at-home care to vulnerable populations...
HTG and Icahn School of Medicine at Mount Sinai Announce Bladder Cancer Research Collaboration
HTG’s Innovative Transcriptome Panel Technology to be Leveraged in Retrospective StudiesTUCSON, Ariz., Nov. 17, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics,...
Frontier Medicines Announces the Appointment of Marguerite Hutchinson, J.D., as Chief Business Officer
SOUTH SAN FRANCISCO, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock...
OWP Pharmaceuticals Announces IND Authorization for the First-Ever Oral Liquid Formulation of Atomoxetine Hydrochloride for the Treatment of Attention Deficit Hyperactivity Disorder
NAPERVILLE, Ill., Nov. 17, 2021 (GLOBE NEWSWIRE) -- OWP Pharmaceuticals, Inc. is a privately held, commercial-stage neuroscience specialty pharmaceutical company,...
ORYZON Enrolls First Patient in EVOLUTION, a Phase IIb Clinical Trial With Vafidemstat in Schizophrenia
Primary objectives: to assess the effect of vafidemstat to address negative and cognitive symptoms in schizophreniaPhase IIb adaptive trial planning...
CoImmune, Inc. Announces Research Collaboration with Yeda Research and Development Company Ltd.
The agreement will support research on applications of the Synthetic Immune Niche technology, developed at the Weizmann Institute of Science...
Fulcrum Therapeutics® Appoints Sonja L. Banks to its Board of Directors
CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives...
Aquestive Therapeutics to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference
WARREN, N.J., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and...
